reports
BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Me...
BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting PHILADELPHIA and VANCOUVER, British Columbia, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting preclinical Bria-OTS+ data at a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, held November 7-9, 2025, in National Harbor, ...
BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Pe...
BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal Data from BriaCell and the US National Cancer Institute (NCI) support the cancer cell killing potential of BriaCell’s Bria-OTS+ platformBria-OTS+, a novel personalized, off-the-shelf, semi-allogeneic cellular immunotherapy may address urgent unmet medical needs for patients with cancer This study was conducted in collaboration with the NCI PHILADELPHIA and VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“Bria...
BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prost...
BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+TM clinical supply and support Phase 1/2a trial in metastatic prostate cancerExpands Bria-OTS+ novel personalized off-the-shelf immunotherapy platform to prostate cancer, an urgent unmet medical needPrincipal Investigator: Dr. William Oh, MD, Yale Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX...
BriaCell Announces Proposed Effective Date of Share Consolidation
BriaCell Announces Proposed Effective Date of Share Consolidation PHILADELPHIA and VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company’s board of directors has approved the consolidation (the “Consolidation”) of the Company’s issued and outstanding common shares (the “Common Shares”) on the basis of one (1) post-Consolidation Common Share for every t...
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for ...
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer PHILADELPHIA and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce its acceptance into Memorial Sloan Kettering Cancer Center’s (MSK’s) Therapeutics Accelerator 2025 Cohort program. This project aims to accelerate the clinical development of Bria-OTS+, BriaCell’s ne...
BriaCell Announces Proposed Effective Date of Share Consolidation
BriaCell Announces Proposed Effective Date of Share Consolidation PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company’s board of directors has approved the consolidation (the “Consolidation”) of the Company’s issued and outstanding common shares (the “Common Shares”) on the basis of one (1) post-Consolidation Common Share for every t...
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer...
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study PHILADELPHIA and VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces the addition of UCLA Health Jonsson Comprehensive Cancer Center, a leading cancer center in California, to its ongoing pivotal Phase 3 clinical study (Bria-ABC, NCT06072612) evaluating Bria-IMT™ in combination with a checkpoint inh...
BriaCell Awarded New Zealand Patent for its Whole Cell Technology
BriaCell Awarded New Zealand Patent for its Whole Cell Technology PHILADELPHIA and VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces that it has been granted New Zealand Patent No. 785587 titled “WHOLE-CELL CANCER VACCINES AND METHODS FOR SELECTION THEREOF”. The patent covers methods of selecting its whole-cell cancer immunotherapy technology for subjects with cancer...
BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-On...
BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents TILsRx platform designed to overcome immune suppression and T cell exhaustion to activate tumor-infiltrating lymphocytes (TILs) Multivalent technology enables simultaneous engagement of multiple cancer-associated and immune pathway targetsA preferred tolerability profile is expected due to selective cancer cell targeting within the tumor microenvironment (TME)TILsRx platform early agents include antibodies to B7-H3, an immune checkpoint found in several cancers including pr...
BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025
BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025 PHILADELPHIA and VANCOUVER, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces two clinical data poster presentations at the European Society for Medical Oncology (ESMO) Congress 2025 Annual Meeting taking place October 17 – 21 in Berlin, Germany. The titles of the poster presentations are listed below. #8212:...
BriaCell Therapeutics Announces Closing of $15 million Public Offering
BriaCell Therapeutics Announces Closing of $15 million Public Offering PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its best-efforts public offering of 12,000,000 units. Each unit consists of one common share (or one pre-funded warrant (“Pre-Funded Warrant”) in lieu thereof) and one warrant (the “Warrants”). Each unit was sold ...
BriaCell Therapeutics Announces Pricing of $15 million Public Offering
BriaCell Therapeutics Announces Pricing of $15 million Public Offering PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts public offering of 12,000,000 units. Each unit consists of one common share (or pre-funded warrant (“Pre-Funded Warrant”) in lieu thereof) and one warrant (the “Warrants”). Each unit is being sold t...
BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer
BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce the addition of a key clinical site, Mayo Clinic, to its ongoing pivotal Phase 3 clinical study (ClinicalTrials.gov as ) in metastatic breast cancer. BriaCell’s Phase 3 study now has 69 active clinical sites across 15 state...
BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® an...
BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer Median Overall Survival (OS) of 13.9 months in triple negative breast cancer (TNBC) exceeds Trodelvy (11.8 months) and doubles control (6.9 months)OS of 17.3 months in HR+ metastatic breast cancer surpasses Trodelvy (14.4 months) and control (11.2 months)No treatment related discontinuations reported PHILADELPHIA and VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”)...
BriaCell Reports Complete and Sustained Resolution of Brain Metastasis...
BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient [IMAGES BELOW] Sustained complete resolution of temporal lobe brain metastasis and continued orbital tumor reduction after >18 months of treatment“Eye bulging” metastatic breast cancer patient had failed 8 prior regimens, including antibody-drug conjugate (ADC) therapyPatient remains on BriaCell’s Phase 2 study with 29 treatment cycles completed PHILADELPHIA and VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- BriaCell ...
BriaCell Patient Achieves Sustained Complete Resolution of Lung Metast...
BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study [IMAGES BELOW] Complete resolution maintained at 6 months in first patient treated with BriaCell’s Bria-OTS in Phase 1/2a studyNo treatment limited toxicities observedPatient remains on study with stable disease elsewhere PHILADELPHIA and VANCOUVER, British Columbia, July 09, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to...
BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Yea...
BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer 52% of BriaCell’s most-recent 25-patient cohort* have surpassed the one-year survival milestone, exceeding current standard of care in similar patients11 patients remain alive as of recent contact, including one patient at 38.3 months and another at 30.3 months Survival benefit observed in heavily pre-treated patients, including those who failed treatment with checkpoint inhibitors (CPIs) and antibody-drug conjugates (ADCs) PHILADELPHIA and VANCOUVER, British Columbia, July 08, 2...
BriaCell Highlights Additional Phase 3 Clinical Sites Including Los An...
BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven add 30 satellite locations to enroll patients in BriaCell’s pivotal Phase 3 studyBriaCell’s Phase 3 study currently has 58 active clinical sites across 15 states, including Smilow Cancer Hospital, Los Angeles Cancer Network, University of Arizona, DHR Health Oncology Institute, Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fred...
BriaCell Announces Positive Recommendation from Data Safety Monitoring...
BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer Independent DSMB identifies no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor Review marks third consecutive positive recommendation by DSMBStudy is being conducted under FDA Fast Track Designation PHILADELPHIA and VANCOUVER, British Columbia, June 24, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a...
BriaCell Announces Virtual Investor Presentations on Thursday, June 12...
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26 PHILADELPHIA and VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces today that the Company will be conducting two virtual investor presentations on Thursday, June 12, at 12:00 PM EDT and on Thursday, June 26, at 12:00 PM EDT, arranged by Renmark Financial Communications Inc. Briace...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.